BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12629636)

  • 1. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART.
    Monno L; Punzi G; Scarabaggio T; Saracino A; Brindicci G; Fiore JR; Iambrenghi OC; Di Stefano M; Pastore G; Angarano G
    J Med Virol; 2003 May; 70(1):1-9. PubMed ID: 12629636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phylogeny and resistance profiles of HIV-1 POL sequences from rectal biopsies and blood.
    Katzenstein TL; Petersen AB; Storgaard M; Obel N; Jensen-Fangel S; Nielsen C; Jørgensen LB
    J Med Virol; 2010 Jul; 82(7):1103-9. PubMed ID: 20513071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.
    Bon I; Gibellini D; Borderi M; Alessandrini F; Vitone F; Schiavone P; Re MC
    J Clin Virol; 2007 Apr; 38(4):313-20. PubMed ID: 17306618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy.
    White NC; Israel-Biet D; Coker RJ; Mitchell DM; Weber JN; Clarke JR
    J Med Virol; 2004 Mar; 72(3):352-7. PubMed ID: 14748057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
    Yu M; Kabat W; Wang J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
    Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
    J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
    Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
    Verhofstede C; Van Wanzeele F; Van Der Gucht B; Pelgrom J; Vandekerckhove L; Plum J; Vogelaers D
    J Med Virol; 2007 Sep; 79(9):1254-60. PubMed ID: 17607772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma.
    Poles MA; Elliott J; Vingerhoets J; Michiels L; Scholliers A; Bloor S; Larder B; Hertogs K; Anton PA
    J Infect Dis; 2001 Jan; 183(1):143-8. PubMed ID: 11087199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.